Virginia Law Raises Red Flags For Biosimilar Industry

Law360, New York (April 1, 2013, 7:32 PM EDT) -- Virginia's new law restricting a pharmacist's ability to swap a biosimilar for a pricey name-brand biologic drug is the first of what could likely become many state laws limiting access to biosimilars, experts say, posing a new threat to the fledgling industry before it even gets off the ground.

States, which regulate pharmacies, are one of the fronts in the regulatory war over biosimilars. How easily biosimilars can be swapped for originator biologics is one of the many factors that will determine whether biosimilars, more complex...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.